As Vertex preps for exa-cel launch, exec touts 'very large' opportunity but tempers early expectations

After a long development road, the first CRISPR-based gene editing therapy recently cleared a FDA advisory committee and appears to be nearing its U.S. launch. Vertex Pharmaceuticals, awaiting the potential approval, is busy laying the groundwork for the med's debut.